NMNathalie Mougenot

Nathalie Mougenot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathalie Mougenot has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Maternal obesity accelerates cardiomyocyte maturation and programs adult heart dysfunction in offspring

    by Dounia Farhi, Gilles Dilanian, Erminia Donnarumma, Nicolas Pataluch, Louis Montagne, Camille Blandin, Nathalie Mougenot, Timothy Wai, Céline Galés, Elise Balse

    Rationale: Maternal obesity increases cardiovascular risk in offspring, but the developmental mechanisms linking early-life metabolic stress to adult heart dysfunction remain poorly understood, and whether maternal obesity alters the postnatal maturation of the cardiomyocyte itself has not been addressed. Objective: To determine whether maternal high-fat diet alters the developmental trajectory of postnatal cardiomyocyte maturation and its functional consequences in adult offspring. Methods: In a rat model of maternal high-fat diet, longitudinal echocardiographic and invasive hemodynamic phenotyping were combined with transcriptomic, lipidomic, and ultrastructural analyses across four postnatal stages. Results: Offspring exposed to maternal high-fat diet displayed accelerated postnatal cardiac maturation, with premature activation of contractile, calcium-handling and metabolic gene programs, concentric hypertrophy, and enhanced systolic performance in juvenile life. This precocious maturation was not sustained: by adulthood, ejection fraction and intrinsic myocardial contractility progressively declined, coinciding with disorganization of sarcomeres, intercalated discs, and excitation-contraction coupling proteins, in the absence of fibrosis, lipid accumulation or major mitochondrial respiratory dysfunction. Conclusions: These findings reveal accelerated cardiomyocyte maturation as a developmental mechanism linking maternal obesity to long-term cardiac vulnerability, with cardiomyocyte cytoarchitecture disruption emerging as an early hallmark that precedes overt systolic failure.

  • Epicardial Fat Drives Macrophage Response in Atrial Cardiomyopathy

    by Laure Crepin, Abhilash Dasari, Nathalie Mougenot, Eva Trenquier, Francois Lanthiez, Ibrahim Abdou, Maria Mihoc, Alexandre de Raymon-Cahuzac, Maharajah Ponnaiah, Esma Karkeni, et al.

    BACKGROUND: Inflammation is associated with atrial fibrillation (AF), but its precise impact on the long-term progression of the AF substrate, also called atrial cardiomyopathy (ACM), remains debated. METHODS: Human atria specimens were used for spatial transcriptomic, histology, epicardial progenitor cell (EPDCs) culture and immunofluorescence. Atria removed from B6J mice fed a high fat diet (HFD) were evaluated at 2 and 4 months of diet with single-cell RNA sequencing, microscopy and flow cytometer. Lyve1-resident macrophages deficient and CCR2 (C-C chemokine receptor type 2) knockout mice and their wild type littermates were evaluated in terms of ACM, cardiac structure, metabolic diseases, histology, immune cells characterization and key molecular markers. Olink assay was performed to screen plasma samples and the cellular secretome for various cytokines. Primary THP1-derived macrophages were cocultured with EPDCs and evaluated for myofibroblast differentiation. RESULTS: Macrophage subpopulations were mainly confined in the EAT of human atria. In a mouse model of obesity and ACM, macrophage recruitment was associated with atrial adiposity. In addition, Lyve1 + -resident and CCR2+ monocyte-derived macrophages were identified in obese mouse atria. Depleting Lyve1 + -macrophages in mice prevented early fat expansion and led to myocardial dystrophy, while CCR2 + -macrophage depletion prevented fibro-fatty remodeling, atrial dilation, and AF. CONCLUSIONS: These data highlight the pivotal role of macrophages in atrial adiposity, in particular that of Lyve1 + -macrophages during adipose tissue expansion.


  • Open Access

    CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model

    by Céline Marigny, Gaëlle Revet, Anne Berger, Morgane Boulch, Nathalie Mougenot, Zhenlin Li, Béatrice Corre, Mégane Lemaitre, Axelle Bois, Clara Castelli, et al.

    Background: Chimeric Antigen Receptor (CAR)-T cells therapy has revolutionized the treatment of hematological cancers and are currently redirected towards non-malignant diseases. If correction of the gene defect remains the cornerstone of the treatment of Duchenne Muscular Dystrophy (DMD), the disease-associated fibrosis can limit its efficacy. We thus assessed the effects of eliminating cardiac fibrosis of DMD by CAR-T cells targeting Fibroblast Activation Protein (FAP), a protein strongly expressed by activated fibroblasts. Methods: In vitro CAR-T cells expressing both FAP and a green fluorescent probe (GFP) were first co-cultured with FAP + of FAP- target cells to check for FAP-expressing lymphocyte activation. Then, anti-FAP CAR-T cells were intravenously delivered in a dystrophic murine model (D2. mdx ), following lymphodepletion, to investigate the kinetics, biodistribution, cardiac functional and anti-fibrotic effects of anti-FAP CAR-T cells compared with control lymphocytes engineered to only express GFP. The mechanism of action at a cellular level was assessed by single-cell RNA-sequencing of harvested hearts. Results: In vitro anti-FAP CAR-T cells were successfully activated when co-cultured with FAP + target cells. In a dystrophic murine model (D2. mdx ), anti-FAP CAR-T cells, intravenously delivered following lymphodepletion, homed to the heart and skeletal muscles, where they decreased FAP and fibrosis-associated genes. Single-cell RNA-sequencing linked these changes to a decrease in a definite cluster of fibrogenic fibroblasts. Concomitantly, anti-FAP CAR-T cells improved cardiac function compared to control mice injected with GFP-transduced T lymphocytes or bovine serum albumin used as negative controls. Conclusions: These results suggest that anti-FAP CAR-T cells could be efficient for mitigating fibrosis and thus complement gene therapy of DMD. More generally, their therapeutic benefits pave the way for potential applications extending to other fibrosis-associated diseases.

  • Open Access

    Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in LMNA Mutation-Induced Dilated Cardiomyopathy

    by Marie Kervella, Charlotta S. Behrens, Cécile Peccate, Zoheir Guesmia, Fiorella Grandi, Nathalie Mougenot, Anne Forand, Azzouz Charrabi, Guy Brochier, Ramaroson Andriantsitohaina, et al.

    BACKGROUND: Dilated cardiomyopathy caused by LMNA mutations is a severe cardiac condition marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, which collectively impair left ventricular function and increase the risk of heart failure. Although the disease has been well characterized, a lack of insight into the pathogenesis has impeded the development of therapies. METHODS: Here, we employed human induced pluripotent stem cells (hiPSCs) derived from a patient carrying a LMNA point mutation (c.665A>C, p.His222Pro), alongside a murine model carrying the same mutation, to investigate the functional and molecular abnormalities driving dilated cardiomyopathy. RESULTS: We demonstrated that LMNA patient-derived cardiomyocytes and engineered heart tissues exhibited elevated diastolic calcium levels and reduced sensitivity to external calcium, respectively, as well as hypocontractility. These cells also displayed nuclear shape abnormalities in 2-dimensional and 3-dimensional, a hallmark of LMNA -associated dilated cardiomyopathy, associated with disrupted chromosome spatial organization and altered gene expression profiles. Transcriptomic analysis revealed dysregulation of extracellular matrix remodeling and significant upregulation of Loxl2 in mutated hiPSC–cardiomyocytes, hiPSC–engineered heart tissues, and mice. Treatment with Simtuzumab, a Loxl2 inhibitor, effectively prevented cardiac dysfunction and fibrosis in vivo. CONCLUSIONS: Taken together, our findings underscore the crucial role of Loxl2 as a therapeutic target and suggest that its inhibition could be a promising strategy to preserve cardiac function in LMNA -associated dilated cardiomyopathy.


  • Open Access

    Gene Therapy with the N-terminal Fragment of Na v 1.5 for Cardiac Channelopathies: A Novel Transcomplementation Mechanism Potentiating the Cardiac Sodium Current

    by Marie Gizon, Marine Caroline Ferrand, Vincent Fontaine, Nathalie Mougenot, Pierre-Léo Laporte, Nathalie Gaborit, Fabrice Extramiana, Isabelle Baró, Pascale Guicheney, Flavien Charpentier, et al.

    BACKGROUND: Cardiac channelopathies, caused by mutations in ion-channel genes, can lead to sudden cardiac death (SCD) via ventricular arrhythmias. Brugada syndrome (BrS) is a rare inherited channelopathy characterized by a unique ECG pattern and a high incidence of ventricular fibrillation leading to SCD in the absence of structural heart defects. The main gene responsible for 20-25% of BrS cases is SCN5A , encoding the cardiac sodium channel α-subunit Na v 1.5, which carries the sodium current ( I Na ) responsible for the rapid depolarization phase of the action potential (AP). While current treatments do not target the genetic cause of channelopathies, this study explores the therapeutic potential of overexpressing the N-terminal region of Na v 1.5 (Nter) to restore electrical activity by rescuing I Na , in the context of SCN5A deficiency. METHODS: We overexpressed the Nter peptide using viral vectors in Scn5a +/- mice, in CRISPR/Cas9 edited- SCN5A +/- cardiomyocytes derived from induced-pluripotent stem cells (iPSC-CMs) and in BrS patient iPSC-CMs. We assessed molecular and functional effects of Nter overexpression in vitro and in vivo by measuring Na v 1.5 subcellular expression and electrophysiological activity and by recording ECGs and arrhythmias. RESULTS: Whereas Scn5a +/- mice showed an impaired I Na associated with a slowed-cardiac conduction characteristic of the BrS phenotype, cardiac-specific overexpression of Nter corrected AP parameters by restoring I Na density in Scn5a +/- mouse cardiomyocytes. This increase in I Na density was caused by a translocation of Na v 1.5 to the cell membrane in Nter-overexpressing mice. Most importantly, Nter overexpression normalized atrioventricular and ventricular conduction and protected Scn5a +/- mice from arrhythmias triggered by programmed electrical stimulation. Similarly, Nter overexpression in SCN5A +/- human iPSC-CMs led to a 2-fold increase in Na v 1.5 cell-surface expression, resulting in normalization of I Na and AP parameters and abolition of early after depolarizations observed during spontaneous AP recordings. Similar results were obtained in iPSC-CMs derived from a BrS patient, confirming the potential of this therapy in human models. CONCLUSIONS: This study identified a novel therapeutic peptide effective in restoring cardiac excitability in animal and cellular models of BrS, paving the way for future development of therapies for life-threatening arrhythmias in patients with SCN5A deficiency.


  • Open Access

    Thioredoxin‐1 and its mimetic peptide improve systolic cardiac function and remodeling after myocardial infarction

    by Tania Medali, Dominique Couchie, Nathalie Mougenot, Maria Mihoc, Olaf Bergmann, Wouter Derks, Luke I. Szweda, Magdi Yacoub, Saif Soliman, Yasmine Aguib, et al.

    Myocardial infarction (MI) is characterized by a significant loss of cardiomyocytes (CMs), and it is suggested that reactive oxygen species (ROS) are involved in cell cycle arrest, leading to impaired CM renewal. Thioredoxin‐1 (Trx‐1) scavenges ROS and may play a role in restoring CM renewal. However, the truncated form of Trx‐1, Trx‐80, can compromise its efficacy by exerting antagonistic effects. Therefore, a Trx‐1 mimetic peptide called CB3 was tested as an alternative way to restore CMs. This study aimed to investigate the effects of Trx‐1, Trx‐80, and CB3 on mice with experimental MI and study the underlying mechanism of CB3 on CMs. Mouse cardiac parameters were quantified by echocardiography, and infarction size and fibrosis determined using Trichrome and Picro‐Sirius Red staining. The study found that Trx‐1 and CB3 improved mouse cardiac function, reduced the size of cardiac infarct and fibrosis, and decreased the expression of cardiac inflammatory markers. Furthermore, CB3 polarized macrophages into M2 phenotype, reduced apoptosis and oxidative stress after MI, and increased CM proliferation in cell culture and in vivo. CB3 effectively protected against myocardial infarction and could represent a new class of compounds for treating MI.


  • Open Access

    NMRK2 Gene Is Upregulated in Dilated Cardiomyopathy and Required for Cardiac Function and NAD Levels during Aging

    by Cynthia Tannous, Robin Deloux, Ahmed Karoui, Nathalie Mougenot, Dean Burkin, Jocelyne Blanc, Dario Coletti, Gareth Lavery, Zhenlin Li, Mathias Mericskay

    Dilated cardiomyopathy (DCM) is a disease of multifactorial etiologies, the risk of which is increased by male sex and age. There are few therapeutic options for patients with DCM who would benefit from identification of common targetable pathways. We used bioinformatics to identify the Nmrk2 gene involved in nicotinamide adenine dinucleotde (NAD) coenzyme biosynthesis as activated in different mouse models and in hearts of human patients with DCM while the Nampt gene controlling a parallel pathway is repressed. A short NMRK2 protein isoform is also known as muscle integrin binding protein (MIBP) binding the α7β1 integrin complex. We investigated the cardiac phenotype of Nmrk2-KO mice to establish its role in cardiac remodeling and function. Young Nmrk2-KO mice developed an eccentric type of cardiac hypertrophy in response to pressure overload rather than the concentric hypertrophy observed in controls. Nmrk2-KO mice developed a progressive DCM-like phenotype with aging, associating eccentric remodeling of the left ventricle and a decline in ejection fraction and showed a reduction in myocardial NAD levels at 24 months. In agreement with involvement of NMRK2 in integrin signaling, we observed a defect in laminin deposition in the basal lamina of cardiomyocytes leading to increased fibrosis at middle age. The α7 integrin was repressed at both transcript and protein level at 24 months. Nmrk2 gene is required to preserve cardiac structure and function, and becomes an important component of the NAD biosynthetic pathways during aging. Molecular characterization of compounds modulating this pathway may have therapeutic potential.


  • Open Access

    High Fat Diet Stimulates Beta-Oxidation, Alters Electrical Properties and Induces Adipogenicity of Atria in Obese Mice

    by Nadine Suffee, Elodie Baptista, Jérôme Piquereau, Maharajah Ponnaiah, Nicolas Doisne, Farid Ichou, Marie Lhomme, Camille Pichard, Vincent Galand, Nathalie Mougenot, et al.

    Metabolic disorders such as obesity are risk factors of atrial fibrillation, not only by sharing comorbidities but likely through their direct impact on atria, notably its adipogenicity. Here, we submitted mice that lack cardiac adipose tissue to a high fat diet and first studied the atrial metabolomic and lipidomic phenotypes using liquid chromatography-mass spectrometry. We found an increased consumption of free fatty acid by the beta-oxidation and an accumulation of long-chain lipids in atria of obese mice. Free fatty acid was the main substrate of mitochondrial respiration studied in the saponin-permeabilized atrial muscle. Conducted action potential recorded in atrial trabeculae was short, and ATP-sensitive potassium current was increased in perforated patch-clamp atrial myocytes of obese mice. There was histological and phenotypical evidence for an accumulation of adipose tissue in obese mice atria. Thus, an obesogenic diet transforms the energy metabolism, causes fat accumulation and induces electrical remodeling of atria myocardium. HIGHLIGHTS - Untargeted metabolomic and lipidomic analysis revealed that a high fat diet induces profound transformation of atrial energy metabolism with beta-oxidation activation and long-chain lipid accumulation. - Mitochondria respiration studied in atrial myocardial trabecula preferentially used Palmitoyl-CoA as energy substrate in obese mice. - Atria of obese mice become vulnerable to atrial fibrillation and show short action potential due to the activation of K-ATP dependent potassium current. - Adipocytes and fat molecular markers were detected in atria of obese mice together with an inflammatory profile consistence with a myocardial accumulation of fat.

  • Inhibition of miR-223 Expression Using a Sponge Strategy Decreases Restenosis in Rat Injured Carotids

    by Eleonore M’bAya-Moutoula, Alexandre Marchand, Isabelle Six, Noura Bahrar, Tanja Celic, Nathalie Mougenot, Pierre Maitrias, Ziad A. Massy, Anne-Marie Lompreh, Laurent Metzinger, et al.

    Objective: Restenosis is a frequent complication of angioplasty. It consists of a neointimal hyperplasia resulting from progression and migration of vascular smooth muscle cells (VSMC) into the vessel lumen. microRNA miR-223 has recently been shown to be involved in cardiovascular diseases including atherosclerosis, vascular calcification and arterial thrombosis. In this study, our aim was to assess the impact of miR-223 modulation on restenosis in a rat model of carotid artery after balloon injury. Methods: The over and down-expression of miR-223 was induced by adenoviral vectors, containing either a pre-miR-223 sequence allowing artificial miR-223 expression or a sponge sequence, trapping the native microRNA, respectively. Restenosis was quantified on stained rat carotid sections. Results: In vitro, three mRNA (Myocyte Enhancer Factor 2C (MEF2C), Ras homolog gene family, member B (RhoB) and Nuclear factor 1 A-type (NFIA)) reported as miR-223 direct targets and known to be implicated in VSMC differentiation and contractility were studied by RT-qPCR. Our findings showed that down-expression of miR-223 significantly reduced neointimal hyperplasia by 44% in carotids, and was associated with a 2-3-fold overexpression of MEF2C, RhoB and NFIA in a murine monocyte macrophage cell line, RAW 264.7 cells. Conclusions: Down-regulating miR-223 could be a potential therapeutic approach to prevent restenosis after angioplasty.